A kind of oral pharmaceutical composition for treating capillary leak syndrome

A technology for capillary leak syndrome, applied in drug combinations, cardiovascular system diseases, pharmaceutical formulations, etc., can solve the unclear pathogenesis of capillary leak syndrome, slow progress in the development of therapeutic drugs, and lack of targeted drugs And other issues

Active Publication Date: 2018-09-18
SHANGHAI TIANLONG PHARMA
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] As of now, due to the unclear pathogenesis of capillary leak syndrome and other issues, the research and development of related therapeutic drugs is slow, and there is a lack of targeted drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of oral pharmaceutical composition for treating capillary leak syndrome
  • A kind of oral pharmaceutical composition for treating capillary leak syndrome
  • A kind of oral pharmaceutical composition for treating capillary leak syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1 Granules for the treatment of capillary leak syndrome and its preparation

[0028] Table 1

[0029]

[0030] Preparation:

[0031] A: Take danshensu and pimavanserin tartrate and pass through a 100-mesh sieve respectively, and mix well.

[0032] B: Take lactose, microcrystalline cellulose, and crospovidone to pass through a 100-mesh sieve, and mix well. where lactose is used

[0033] The amount is 2.2 times of the weight of danshensu; the amount of microcrystalline cellulose is 1.2 times of the weight of danshensu; the amount of crospovidone is 0.13 times of the weight of danshensu.

[0034] C: Mix the powder obtained in step A and step B evenly.

[0035] D: Take povidone K30 and add water and stir well to make a liquid dispersion system. Wherein the consumption of povidone K30 is 0.18 times of the weight of Danshensu; the consumption of water is 32.5 times of the weight of povidone K30.

[0036] E: The liquid dispersion system obtained in step D is a...

Embodiment 2

[0038] Example 2 Granules for the treatment of capillary leak syndrome and its preparation

[0039] Table 2

[0040]

[0041] Preparation:

[0042] A: Take danshensu and pimavanserin tartrate and pass through a 100-mesh sieve respectively, and mix well.

[0043] B: Take lactose, microcrystalline cellulose, and crospovidone to pass through a 100-mesh sieve, and mix well. where lactose is used

[0044] The amount is 2.2 times of the weight of danshensu; the amount of microcrystalline cellulose is 1.2 times of the weight of danshensu; the amount of crospovidone is 0.13 times of the weight of danshensu.

[0045] C: Mix the powder obtained in step A and step B evenly.

[0046] D: Take povidone K30 and add water and stir well to make a liquid dispersion system. Wherein the consumption of povidone K30 is 0.18 times of the weight of Danshensu; the consumption of water is 32.5 times of the weight of povidone K30.

[0047] E: The liquid dispersion system obtained in step D is a...

Embodiment 3

[0049] Example 3 Granules for the treatment of capillary leak syndrome and its preparation

[0050] table 3

[0051]

[0052] Preparation:

[0053]A: Take danshensu and pimavanserin tartrate and pass through a 100-mesh sieve respectively, and mix well.

[0054] B: Take lactose, microcrystalline cellulose, and crospovidone to pass through a 100-mesh sieve, and mix well. where lactose is used

[0055] The amount is 2.2 times of the weight of danshensu; the amount of microcrystalline cellulose is 1.2 times of the weight of danshensu; the amount of crospovidone is 0.13 times of the weight of danshensu.

[0056] C: Mix the powder obtained in step A and step B evenly.

[0057] D: Take povidone K30 and add water and stir well to make a liquid dispersion system. Wherein the consumption of povidone K30 is 0.18 times of the weight of Danshensu; the consumption of water is 32.5 times of the weight of povidone K30.

[0058] E: The liquid dispersion system obtained in step D is ad...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicine, and particularly relates to an oral pharmaceutical composition for treating capillary leak syndrome. The oral pharmaceutical composition for treating capillary leak syndrome is prepared from pharmaceutically acceptable pharmaceutical adjuvants, tanshinol, and pimavanserin tartrate; the ratios of the tanshinol and the pimavanserin tartrate are, by weight, 12-24 parts of the tanshinol and 1-5 parts of the pimavanserin tartrate. The dosage form of the oral pharmaceutical composition for treating the capillary leak syndrome is preferably granules. According to the composition, the pimavanserin tartrate has synergistic effects on the tanshinol, and the tanshinol and the pimavanserin tartrate significantly reduce capillary permeability of a rat model of the capillary leak syndrome.

Description

technical field [0001] The invention belongs to the field of medicine, in particular to an oral pharmaceutical composition for treating capillary leak syndrome. Background technique [0002] Capillary leak syndrome (Capillary leak syndrome, CLS) is a sudden capillary hyperpermeability disease caused by increased vascular permeability; it often manifests as acute and progressive generalized edema, hypoproteinemia, blood pressure and central Symptoms such as decreased venous pressure, weight gain, and hemoconcentration, and multiple organ failure may occur in severe cases. The occurrence of capillary leak syndrome will worsen the condition of critically ill patients, increase the difficulty of treatment, and even lead to the death of patients in a short period of time. [0003] The exact pathogenesis of capillary leak syndrome is still unclear. Some researchers put forward some hypotheses about the pathogenesis of capillary leak syndrome (Er Qidong. Clinical Research Progres...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/192A61K31/4468A61K9/16A61K47/38A61P9/14
CPCA61K9/1652A61K31/192A61K31/4468A61K2300/00
Inventor 王全政朱会娟孙振秋姚蕾张玉清李月芹
Owner SHANGHAI TIANLONG PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap